Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Extension Study to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)
Conditions
Interventions
Placebo
Ianalumab
Locations
127
United States
Pinnacle Research Group Llc
Anniston, Alabama, United States
Providence Medical Center
Burbank, California, United States
Advanced Medical Research
La Palma, California, United States
Millennium Clinical Trials
Westlake Village, California, United States
University of Colorado Denver
Aurora, Colorado, United States
Clinical Res Of W Florida
Clearwater, Florida, United States
Start Date
May 21, 2024
Primary Completion Date
April 8, 2030
Completion Date
April 5, 2032
Last Updated
March 13, 2026
NCT07526350
NCT06875960
NCT06335979
NCT06647069
NCT07371468
NCT05843643
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions